<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2213">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708912</url>
  </required_header>
  <id_info>
    <org_study_id>8796</org_study_id>
    <nct_id>NCT04708912</nct_id>
  </id_info>
  <brief_title>Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)</brief_title>
  <acronym>8796</acronym>
  <official_title>TUSEB-Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basaksehir Cam &amp; Sakura Şehir Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basaksehir Cam &amp; Sakura Şehir Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will study nasopharunx microbiota composition, RNA sequences and in vitro&#xD;
      cytokines production by peripheral blood cells of COVID-19 patients (both mild-moderate and&#xD;
      severe cases) (comparing with convalescent patients and healthy controls).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will compare study parameters (basal) between mild-moderate and severe&#xD;
      COVID-19 patients and with other study groups (i.e. convalescent and healthy controls).&#xD;
      Nasopharunx microbiota dysbiosis, in vitro cytokines production profile, and peripheral blood&#xD;
      flocytometric results of the four study groups will be compared.&#xD;
&#xD;
      In vitro cytokines production will be studied and compared in Nill (No antigens) and Mitojen&#xD;
      (Cocktail of antigens) pre-prepared test tubes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of peripheral blood RNA microarray assay</measure>
    <time_frame>First day</time_frame>
    <description>Four study groups, microarray Analysis .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of nasopharunx Microbiota analysis</measure>
    <time_frame>1st day</time_frame>
    <description>Four study groups, metagenomic analysis, to determine abundance and decrease of some species.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of in vitro cytokines production</measure>
    <time_frame>First day</time_frame>
    <description>IL-2, IL-7, IL-10, granulocyte-colony stimulating factor, interferon-p inducible protein 10, monocyte chemo-attracting protein 1, macrophage inflammatory protein 1-α and tumor necrosis factor-α in Nill (no angijen) and Mitojen (Cocktails of antigens)tubes (between 4 study groups)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of peripheral blood cytometry</measure>
    <time_frame>First day</time_frame>
    <description>Four study groups, peripheral blood cytometry; CD3, CD4, CD8, and CD45 rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relation between study parameters</measure>
    <time_frame>First day parameters</time_frame>
    <description>determining the realtion between microbiotme dysbiosis, in vitro cytokines production and peripheral leymphocytes (CD3,CD4, CD8, and CD45) rates and the severity of COVID-19( if any)</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Mild-Moderate COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Severe COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Convalsent (COVID-19)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Healthy persons</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>The study parameters will be obtained at the time of recuirement (Basal)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microbiota and RNA sequencing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults (18-80 yerars ), both gender&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give a written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In ability to give a written consent&#xD;
&#xD;
          -  Using of medications that affect the results of study parameters&#xD;
&#xD;
          -  Presence of malignancy or tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Hursitoglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basaksehir Cam and sakura Sehir Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehmet Hursitoglu, MD</last_name>
    <phone>+902129096000</phone>
    <phone_ext>20527</phone_ext>
    <email>mehmet.hursitoglu@sbu.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bakirkoy Dr.sadi Konuk Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bakirkoy Dr.sadi Konuk Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Microbiota and viral infections</citation>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Basaksehir Cam &amp; Sakura Şehir Hospital</investigator_affiliation>
    <investigator_full_name>Mehmet Hursitoglu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

